NCT00143117已完成2 期
A Phase 2b, Multi-Center, Double-Blind, Placebo-Controlled, Parallel Group Dose Response Study to Assess the Efficacy and Safety of Oral UK-390,957 in Men With Premature Ejaculation
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- Pfizer
- 入组人数
- 460
- 试验地点
- 51
- 主要终点
- Assessment of efficacy and safety
研究概览
简要总结
To determine whether UK-390,957 is an effective and safe treatment for premature ejaculation.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Premature ejaculation as defined by DSM-IV
排除标准
- •History of erectile dysfunction
结局指标
主要结局
Assessment of efficacy and safety
次要结局
- Assessment of Quality of Sexual Life
研究者
研究点 (51)
Loading locations...
相似试验
已完成
2 期
Assessment Of Safety Of UK-390,957EjaculationNCT00219609Pfizer1,058
已完成
2 期
A Study On Concentrations Of 16448 In Blood And The Safety Of This Compound In Healthy Males With Premature EjaculationPremature EjaculationNCT00537459GlaxoSmithKline18
已完成
2 期
Assessment Of Efficacy and Safety Of UK-390,957 In Men With Premature EjaculationEjaculationNCT00219583Pfizer460
已完成
2 期
Assessment Of Efficacy and Safety UK-390,957 In Men With Premature EjaculationEjaculationNCT00219635Pfizer138
终止
2 期
Phase 2 Study of the Safety and Efficacy of UK-500,001 in Adult Patients With COPDPulmonary Disease, Chronic ObstructiveNCT00263874Pfizer324